Watch These Intuitive Surgical Price Levels as Stock Hits Another Record High
Intuitive Surgical shares hit another record high Thursday as investor sentiment runs high amid growing demand for the company's surgical robotics equipment. Monitor these key chart levels.
Canary's Litecoin ETF Takes Big Step Toward Nasdaq Listing
Nasdaq moves forward with Canary Capital's Litecoin fund bid through crucial regulatory filing, signaling a potential third spot crypto ETF.
American Express agrees to pay more than $138M to resolve investigation into sales and marketing
American Express has agreed to pay more than $138 million to resolve a wire fraud investigation related to its sales and marketing practices, federal authorities announced Thursday. The New York-based
How blowout bank earnings and a promising inflation report gave the market a much-needed boost
Wall Street looked set to recover after US banks posted impressive earnings, and inflation data was better than expected.
Stock market today: Nasdaq slide leads stocks lower with earnings, Bessent confirmation hearing in focus
Stocks failed to continue Wednesday's rally as retail sales and fresh earnings from big banks took focus.
Palantir Stock’s (PLTR) Valuation Is Hard to Defend despite White House Ally
Palantir Technologies (PLTR) stock surged following the re-election of Donald Trump to The White House. Despite CEO Alex Karp’s opposition to Trump, the AI software company seems to have found suppo
Why Wall Street stayed mute on Thursday after its best day since November
Wall Street paused, with stocks ending little changed. Strong bank earnings keep rolling in and Trump's Treasury pick fields Senate questions.
Richemont’s Surprise Revenue Gain Lifts Luxury Stocks, Offering Hope to Brand Owners, Investors
Richemont outstripped expectations with a 10 percent jump in revenue during the key holiday quarter, offering hope that luxury's slump might be coming to an end.
American Express to pay $230 million over 'deceitful marketing campaign'
American Express (AXP) agreed to pay a total of about $230 million Thursday to settle allegations of past deceptive marketing practices associated with its wire products.
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
On Wednesday, ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC)